Neurocrine Biosciences grants Chief Medical Officer Eiry Roberts 8,314 stock options, 1,506 restricted stock units

NBIX•2026-11-05

Neurocrine Biosciences granted Chief Medical Officer Eiry Roberts 8,314 stock options and 1,506 restricted stock units on November 4, 2026. The options expire on November 4, 2036.

1. Equity awards

Neurocrine Biosciences granted Chief Medical Officer Eiry Roberts 8,314 stock options and 1,506 restricted stock units on November 4, 2026. The options expire on November 4, 2036.

Sources

Neurocrine Biosciences grants Chief Medical Officer Eiry Roberts 8,314 stock options, 1,506 restricted stock units

Sec

Neurocrine Biosciences grants Chief Medical Officer Eiry Roberts 8,314 stock options, 1,506 restricted stock units

1. Equity awards

Related News

Sabesp announces R$ 2.64 billion interest on equity payment

Definitive Healthcare Q3 revenue falls; withholds guidance

Sangoma Technologies Q1 net income USD -2.885 million

Sources

Neurocrine Biosciences grants Chief Medical Officer Eiry Roberts 8,314 stock options, 1,506 restricted stock units

Caribou Biosciences Q3 revenue declines, to discontinue lead clinical programs

Ultralife Q3 revenue rises on defense sales